BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute of Biomedical Engineering (BME) - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute of Biomedical Engineering (BME)
X-ORIGINAL-URL:https://bme.utoronto.ca
X-WR-CALDESC:Events for Institute of Biomedical Engineering (BME)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220530T150000
DTEND;TZID=America/Toronto:20220530T170000
DTSTAMP:20220530T152312Z
CREATED:20220511T143954Z
LAST-MODIFIED:20220530T152312Z
UID:10000015-1653922800-1653930000@bme.utoronto.ca
SUMMARY:Pitch Competition: Building a Biotech Venture program
DESCRIPTION: \nRegister to join the audience at the 2022 Pitch Competition!\nJoin us in-person on May 30 for the Building a Biotech Venture Pitch Competition to learn how the next generation of regenerative and precision medicine researchers are preparing to translate their discoveries toward impact.\nWatch as six trainee-led teams from the University of Toronto and its affiliated hospitals pitch their ventures to an expert panel of judges. The winning team will receive $25\,000\, and the second-place team will receive $10\,000 in research funding to advance their product concept.\nRegister now\nThe competition is the culmination of Medicine by Design’s Building a Biotech Venture program\, offered in partnership with Precision Medicine Initiative (PRiME)\, the Health Innovation Hub (H2i) and Talk Boutique. Over the last six months\, teams have worked with mentors to advance early-stage company concepts based on their research.\nCome cheer on these up-and-coming entrepreneurs as they showcase their innovative technologies!\nNOTE: This event will be held in-person in accordance with the University of Toronto’s COVID-19 policies. Masks are required in indoor spaces where physical distancing cannot be maintained.\nMeet the judges\nAlberto GalassoElla Korets-Smith Angela MacDonaldRobin QuirkAlberto Galasso  \n \nAlberto Galasso\, PhD\nProfessor of Strategic Management\nRotman School of Management\, University of Toronto\nRead more\nElla Korets-Smith\nElla Korets-Smith\, MBA\, MSc\nChief Business Officer\, Virica Biotech\nRead more\nAngela MacDonald\nAngela McDonald\, PhD\nEntrepreneur-in-Residence\, Versant Ventures\nRead more\nRobin Quirk\nRobin Quirk\, PhD\, MBA\nVice President\, Technology Sourcing & Venture Development\, CCRM\nRead more\nMeet the teams\nAzane Therapeutics\nDelivering the promise of RNA therapy.\nLab: Institute of Biomedical Engineering and Department of Immunology\, University of Toronto\nThis company’s product\, a delivery vehicle for mRNA-based therapies\, has the potential to make it possible for rare diseases to be treated with mRNA. The platform could also apply to regenerative medicine treatments such as stem cell reprogramming and inflammatory disorders.\nDTPX Therapeutics\nDeveloping immunotherapy against hibernating drug tolerant cancer cells for colorectal cancer patients.\nLab: Princess Margaret Cancer Centre\, University Health Network; and Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto.\nWhen individuals are treated for colorectal cancer with standard chemotherapy\, a cell population that’s resistant to treatment can “hibernate” and re-emerge after treatment\, causing the tumour to relapse. DTXP Therapeutics aims to create a platform that can selectively target these hibernating cells to reduce the chance of relapse\, potentially benefiting many types of cancer. \nGlusyn Diagnostics\nAutomated PCR-free diagnostic systems for rapid\, low-cost\, distributed usage.\nLab: Leslie Dan Faculty of Pharmacy\, University of Toronto.\nWith mastitis in dairy cows as a use-case\, this teams aims to develop automated PCR-free diagnostic systems that are shelf-stable and have low manufacturing costs. \nA2O\nReprogramming for recovery.\nLab: Division of Anatomy\, University of Toronto.\nA2O has developed a type of gene therapy to convert toxic brain cells back into healthy cells to treat chronic neurodegenerative disease such as multiple sclerosis and Alzheimer’s disease\, as well as acute neurological injuries such as spinal cord injury. This therapy allows for a targeted approach that can be tailored to disease type\, stage or severity. \nOne Drug\nEnabling next generation drugs.\nLabs: Leslie Dan Faculty of Pharmacy\, University of Toronto; Institute of Biomedical Engineering\, University of Toronto; and Department of Chemistry\, University of Toronto. \nDeveloping clinical point-of-care diagnostic devices that will enable clinicians and drug developers identify patients at risk of adverse drug reactions and/or suboptimal drug response based on their genetic makeup. \nScivance\nDeveloping therapeutics for rare disease.\nLab: Department of Chemical & Physical Sciences\, University of Toronto Mississauga\nOnly five percent of rare diseases have treatments\, and a substantial portion of these rare diseases are caused by genes called fusion oncogenes. This team is developing a proprietary algorithm and multi-disciplinary pipeline which lies at the intersection of medicinal chemistry\, structural biophysics and molecular biology\, which can help develop treatments for these disease drivers.
URL:https://bme.utoronto.ca/event/pitch-competition-building-a-biotech-venture-program/
LOCATION:Leslie Dan Pharmacy Building Room PB B250\, 144 College St\, Toronto\, M5S 3M2\, Canada
CATEGORIES:Events & Workshops
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220531T110000
DTEND;TZID=America/Toronto:20220531T120000
DTSTAMP:20220510T195824Z
CREATED:20220510T192503Z
LAST-MODIFIED:20220510T195824Z
UID:10000008-1653994800-1653998400@bme.utoronto.ca
SUMMARY:Reimagining the Jugular Venous Pressure: The Evolution of a Medical Technology Start-up
DESCRIPTION:Please join us for an ECHO webinar on Tuesday May 31\, 2022 (11 am – 12 pm EST) featuring Dr. Andrew J Smith (CSO and Co-Founder\, JVPLabs). Dr. Smith’s presentation entitled\, “Reimagining the Jugular Venous Pressure: The Evolution of a Medical Technology Start-up”\, will feature an overview of JVPLabs\, its technologies and the story behind its success. JVPLabs is a medical device company founded in 2016 by two physicians\, Dr. Andrew Smith (Emergency Medicine) and Dr. Jason Roberts (Cardiology). The focus of the company is to develop a leading edge non-invasive technology to improve and enable assessment of Congestive Heart Failure (CHF) patients via the JVP height\, in hospital and remotely\, at home. Please see attachment for more details.
URL:https://bme.utoronto.ca/event/reimagining-the-jugular-venous-pressure-the-evolution-of-a-medical-technology-start-up/
CATEGORIES:External Speaker Series
ATTACH;FMTTYPE=image/jpeg:https://bme.utoronto.ca/wp-content/uploads/2022/05/thumbnail_ECHO-Webinar-Andrew-J-Smith-JVPLabs-May-31-2022-Social-media-e1652210852247.jpg
ORGANIZER;CN="Translational Biology and Engineering Program (TBEP)":MAILTO:reception.tbep@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220531T130000
DTEND;TZID=America/Toronto:20220531T140000
DTSTAMP:20220609T150149Z
CREATED:20220525T131335Z
LAST-MODIFIED:20220609T150149Z
UID:10000026-1654002000-1654005600@bme.utoronto.ca
SUMMARY:Faculty Search Candidate Talk
DESCRIPTION:This event will be in person only.
URL:https://bme.utoronto.ca/event/faculty-search-candidate-talk/
LOCATION:Medical Science Building\, Room 3153\, 1 King's College Circle\, Toronto\, Ontario\, M5S 1A8\, Canada
CATEGORIES:BME Faculty Search
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220601T120000
DTEND;TZID=America/Toronto:20220601T130000
DTSTAMP:20220520T151856Z
CREATED:20220520T151856Z
LAST-MODIFIED:20220520T151856Z
UID:10000025-1654084800-1654088400@bme.utoronto.ca
SUMMARY:Modern Toothpaste Technologies: The Role and Use of Hydroxyapatite in Oral Care
DESCRIPTION:Faculty of Dentistry Research Seminar\nDr. Joachim Enax and Dr. Frederic Meyer\nDr. Kurt Wolff GmbH & Co. KG\,\nBielefeld\, GERMANY\nOver the last years synthetic hydroxyapatite has gained increasing attention as a biomimetic/bionic\noral care agent in preventive dentistry due to its high similarity to human tooth enamel. A significant\nand constantly increasing number of published studies demonstrate its efficacy in various fields of\npreventive oral health care. Currently\, both professional and public debate propagates\nhydroxyapatite as a viable biomimetic alternative to the long-established fluoride in oral care. For\nexample\, hydroxyapatite – in contrast to fluorides – can be used as safe and efficient ingredient for\nkids’ toothpastes because it is safe if swallowed and does not present any risk of fluorosis.\nThe presentation will cover the following topics: \n– Modern toothpaste technologies\, toothpaste ingredients and their functions\n– Hydroxyapatite in oral care\n– Synthesis\, characterization\, safety\, and application fields in dentistry\n– Mechanistic studies (in situ\, in vitro): SEM\, TEM\, TMR etc.\n– Modes of action\n– Clinical studies: RCTs on caries prevention\, gingival health\, reduction of dentin hypersensitivity
URL:https://bme.utoronto.ca/event/modern-toothpaste-technologies-the-role-and-use-of-hydroxyapatite-in-oral-care/
LOCATION:Dentistry Building\, The auditorium (DN 19)\, 124 Edward Street\, 124 Edward Street\, Toronto\, Ontario\, Canada
CATEGORIES:External Speaker Series
END:VEVENT
END:VCALENDAR